The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
 
Donna Molaie
No Relationships to Disclose
 
Albert Lai
No Relationships to Disclose
 
Benjamin M. Ellingson
Consulting or Advisory Role - Agios; Bristol-Myers Squibb; Imaging Endpoints; Medicenna; MedQIA; Nativis; Northwest Biotherapeutics; Novogen; Omniox; Roche/Genentech; Siemens; Tocagen
Research Funding - Agios; Roche/Genentech; Siemens
Travel, Accommodations, Expenses - Siemens
 
Thien Nguyen
No Relationships to Disclose
 
Hye Hyun Bahng
No Relationships to Disclose
 
Emese Filka
No Relationships to Disclose
 
Stacey Green
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - BBI Healthcare
Travel, Accommodations, Expenses - BBI Healthcare
 
Whitney B. Pope
Consulting or Advisory Role - Blue Earth Diagnostics; Bracco Diagnostics; Carl Zeiss Meditec
 
Mei Leng
No Relationships to Disclose
 
William H. Yong
Consulting or Advisory Role - Amgen
 
Richard M. Green
Research Funding - Boston Biomedical; DelMar Pharmaceuticals
 
Jonathan Polikoff
No Relationships to Disclose
 
Liz Spier
No Relationships to Disclose
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Guidepoint Global; Merck; Novocure; Regeneron; tocagen
Speakers' Bureau - Prime Oncology
Research Funding - Bristol-Myers Squibb; Celldex; FORMA Therapeutics; Merck; Northwest Biotherapeutics; tocagen
Travel, Accommodations, Expenses - Oncoceutics
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics
 
Andrew B. Lassman
Honoraria - Abbott Molecular; WebMD
Consulting or Advisory Role - Abbvie; Agios; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; QED Therapeutics; SapVax
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Amgen (Inst); Bayer (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Keryx (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Oncoceutics
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; DelMar Pharmaceuticals; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; Karyopharm Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pascal Biosciences; Pfizer; Puma Biotechnology; QED Therapeutics; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Phioanh Leia Nghiemphu
Consulting or Advisory Role - Abbvie
Research Funding - Genentech/Roche; Novartis